Journal article
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
TM Severson, DM Wolf, C Yau, J Peeters, D Wehkam, PC Schouten, SF Chin, IJ Majewski, M Michaut, A Bosma, B Pereira, T Bismeijer, L Wessels, C Caldas, R Bernards, IM Simon, AM Glas, S Linn, L van't Veer
Breast Cancer Research | BMC | Published : 2017
Open access
Abstract
Background: Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between BRCA1-like and non-BRCA1-like tumors. We hypothesized that these tumors may also be more sensitive to PARP inhibitors than standard treatments. Methods: A diagnostic gene expression signature (BRCA1ness) was developed using a centroid model with 128 triple-negative breast cancer samples from the EU FP7 RATHER project. This BRCA1ness signature was then tested in HER2-negative patients (n=116) from the I-SPY 2 TRIAL who received an oral PARP inhibitor veliparib in combination with carboplatin (V-C), or ..
View full abstractGrants
Awarded by Seventh Framework Programme
Funding Acknowledgements
This study was supported by the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (Rational Therapy for Breast Cancer) (protect number: 258967) (www.ratherproject.com) and I-SPY 2 TRIAL investigators (ispy2.org).